The first clinical-stage dual-payload conjugate
Chengdu Kanghong's KH815 enters human testing this month.
FDA red and green lights: March 2025
Cabometyx and Pluvicto get the nod, but it’s another knockback for rivoceranib plus camrelizumab.
The month ahead: April’s upcoming events
AACR approaches, along with ASCO abstract titles.
Summit looks to repeat ivo's Chinese success
Akeso scored in the Harmoni-A trial, and now Summit must do the same in Harmoni.
iTeos, and Roche's RAS mystery, start phase 1
First-in-human study listings include EOS-215 and RO7673396.
MediLink beats Sotio to the punch
YL217 will enter phase 1 before Sotio's similarly acting rival, licensed from Biocytogen.
